KANGHUI PHARMACEUTICAL(SH:603139) Shang Hai Zheng Quan Bao·2025-10-27 23:10Core Viewpoint - The lawsuit involving Shaanxi Kanghui Pharmaceutical Co., Ltd. has progressed to the second instance, with the appellant withdrawing the appeal, which is not expected to negatively impact the company's profits for the current or future periods [2][6][7]. Group 1: Lawsuit Background - The company initiated a lawsuit against Hubei Kelaivi Biological Pharmaceutical Co., Ltd. in September 2024 regarding the payment of equity repurchase deposit and repurchase amount [3]. - The first-instance judgment was received in May 2025, and an appeal was filed by Yiwikangyuan (Beijing) Pharmaceutical Technology Co., Ltd. in July 2025 [3]. Group 2: Recent Developments - The company recently received a civil ruling from the Shaanxi Intermediate People's Court, allowing the appellant to withdraw the appeal, which means the first-instance judgment will take effect [3][5]. - The second-instance case acceptance fee was 110,885 yuan, with a reduced fee of 55,442.5 yuan to be borne by the appellant [4]. Group 3: Financial Implications - The amount involved in the lawsuit is 37.994 million yuan plus interest [6]. - The withdrawal of the appeal is anticipated to have no adverse effect on the company's current or future profits, and the company will continue to monitor the situation closely [7].